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A B S T R A C T
NAD metabolism and the NAD biosynthetic enzymes nicotinamide nucleotide adenylyltransferases (NMNATs)
are thought to play a key neuroprotective role in tauopathies, including Alzheimer’s disease. Here, we in-
vestigated whether modulating the expression of the NMNAT nuclear isoform NMNAT1, which is important for
neuronal maintenance, inﬂuences the development of behavioral and neuropathological abnormalities in htau
mice, which express non-mutant human tau isoforms and represent a model of tauopathy relevant to Alzheimer’s
disease. Prior to the development of cognitive symptoms, htau mice exhibit tau hyperphosphorylation associated
with a selective deﬁcit in food burrowing, a behavior reminiscent to activities of daily living which are impaired
early in Alzheimer’s disease. We crossed htau mice with Nmnat1 transgenic and knockout mice and tested the
resulting oﬀspring until the age of 6 months. We show that overexpression of NMNAT1 ameliorates the early
deﬁcit in food burrowing characteristic of htau mice. At 6 months of age, htau mice did not show neurode-
generative changes in both the cortex and hippocampus, and these were not induced by downregulating
NMNAT1 levels. Modulating NMNAT1 levels produced a corresponding eﬀect on NMNAT enzymatic activity but
did not alter NAD levels in htau mice. Although changes in local NAD levels and subsequent modulation of NAD-
dependent enzymes cannot be ruled out, this suggests that the eﬀects seen on behavior may be due to changes in
tau phosphorylation. Our results suggest that increasing NMNAT1 levels can slow the progression of symptoms
and neuropathological features of tauopathy, but the underlying mechanisms remain to be established.
1. Introduction
NAD metabolism is increasingly implicated in a variety of biological
functions, including regulation of gene transcription, lifespan, cell
death, circadian rhythm and glucose homeostasis [1,2]. The three
mammalian isoforms of the central NAD biosynthetic enzyme, nicoti-
namide mononucleotide adenylyltransferases (NMNATs), have recently
emerged as crucial players in neuronal maintenance and protection
[3–6]. They share the same enzymatic activity but a diﬀerent sub-
cellular distribution [7,8]. Cytoplasmic NMNAT2 has been recently
described as an axon survival factor, a role which is linked to its en-
zymatic activity, while NMNAT1 appears to have a similar function in
neuronal cell bodies [6]. The discovery that loss-of-function mutations
in the nuclear isoform NMNAT1 cause Leber Congenital Amaurosis
(LCA), a human nervous system disorder characterized by degeneration
of retinal neurons and blindness [9–11], directly links NMNAT1 to
neuron survival. Nuclear NMNAT1 has also been associated with neu-
roprotection in models of human disorders, such as PolyQ toxicity and
hypoxic ischemia, with a mechanism correlated to the enzymatic ac-
tivity and its reported chaperone function [12,13]. In Drosophila a
single, homogenously distributed NMNAT isoform has been reported,
whose loss causes neuronal and axonal degeneration [3].
Studies in Drosophila and mice also highlight NMNAT protective
function in models of tauopathies. Neurodegenerative diseases, in-
cluding Alzheimer’s disease (AD), Pick’s disease and frontotemporal
dementia with Parkinsonism linked to chromosome 17 (FTDP-17), are
characterized by the presence of hyperphosphorylated tau protein that
aggregates and forms neuroﬁbrillary tangles (NFTs) [14]. Tau is a
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microtubule-associated protein (MAP) expressed in neurons and nor-
mally localized in axons, where it promotes microtubule assembly and
stabilization, depending on its level of phosphorylation [15,16]. Con-
versely, hyperphosphorylated tau, as seen in tauopathies, is unable to
stabilize microtubule assemblies and sequesters normal tau and other
microtubule stabilizing protein such as MAP1A/MAP1B and MAP2,
leading to disruption of microtubules and axonal transport, ﬁnally re-
sulting in retrograde degeneration and cell death [17]. Furthermore,
abnormally hyperphosphorylated tau leads to the formation of NFTs,
which are associated with cellular toxicity and dementia [17]. Over-
expression of Drosophila NMNAT reduces hyperphosphorylated tau load
and rescues cognitive and locomotor deﬁcits caused by overexpression
of human wild type or mutant tau in Drosophila [18]. Importantly,
NMNAT neuroprotection was also conﬁrmed in a mouse model of
tauopathy, where NMNAT2 was downregulated in both cortex and
hippocampus of mice overexpressing the FTDP-17 associated mutant
tau P301L. In this model, hippocampal-speciﬁc overexpression of either
NMNAT1or NMNAT2 signiﬁcantly reduced hippocampal neuronal loss
[19]. Furthermore, it has been recently shown that overexpression of
NMNAT1, when redistributed in the cytoplasm (cytNMNAT1), pre-
serves cortical functional connectivity and reduces tau aggregation in
the brain of P301S mutant human tau transgenic mice [20]. However,
little is known on the role of NMNAT1 in tauopathies, when its nuclear
subcellular localization is maintained.
We therefore investigated whether modulating the levels of nuclear
NMNAT1 alters the progression of early behavioral dysfunctions and
pathological abnormalities, in the htau mouse model of tauopathy
which has particular relevance to AD [21] by crossing htau mice with
Nmnat1 transgenic and knockout mice [22,23].
The htau mouse is characterized by the expression of non-mutant
human tau, coding for all six human tau isoforms, including three (3R)
and four (4R) microtubule binding domain repeats [21]. This results in
an AD-like pathology characterized by early tau hyperphosphorylation,
redistribution into cell bodies and dendrites as well as accumulation to
form neuroﬁbrillary tangle-like assemblies [21]. We hypothesized that
reducing NMNAT1 levels will accelerate, while overexpressing
NMNAT1 will slow, the progression of behavioral and neurological
features in htau mice. We have extensively characterized the behavioral
phenotype of htau mice with aging and found that they display speciﬁc
early defects in ‘daily life activities’, assessed in the food burrowing test,
from after onset of tau hyperphosphorylation[24].
Here we found that total cellular NAD levels were unaltered by
NMNAT1 modulation in htau mice although downregulating or over-
expressing NMNAT1 signiﬁcantly reduced or increased NMNAT enzyme
activity, respectively. We found that while overexpressing nuclear
NMNAT1 reversed early behavioral deﬁcits characteristic of htau mice
and attenuated tau hyperphosphorylation, downregulating NMNAT1
had subtle eﬀects on these features and did not cause neurodegenera-
tive changes. Our ﬁndings therefore suggest that an increased amount
of nuclear NMNAT1 is protective during the early stages of tauopathy in
htau mice.
2. Materials and methods
2.1. Mice and genotyping
All experimental animals used were bred and housed in groups at
the University of Nottingham Biomedical Service Unit. The animal work
was carried out in accordance with the UK Animals (Scientiﬁc
Procedures) Act of 1986 (under project licences: PPL 40/3482 and 40/
3601), approved by the University of Nottingham Ethical Review
Committee and is reported according to the ARRIVE guidelines [25]. All
mice were maintained at the University of Nottingham and humanely
killed by cervical dislocation. Heterozygous Nmnat1 knockout (KO) and
transgenic mice have been previously described [22,23]. htau mice
(STOCKMapttm1(EGFP)Klt Tg(MAPT)8cPdav/J) were originally purchased
from the Jackson Laboratories (Bar Harbor, ME, USA) as described
previously [24] and crossed with Nmnat1 mutant mice to produce ex-
perimental htau mice with either increased or reduced levels of nuclear
NMNAT1.
Mice were genotyped by PCR using the following primers:
Nmnat1+/−
Forward 5′-CCCAGTCACTAAGACATTCAA-3′
Reverse 5′-CCTTCTTGCTTCCCACGAGG-3′;
Nmnat1 tg
Forward 5′-ACTTCGGCTCACAGCGCG-3′
Reverse 5′-TCCTTGGCCAGCTCGAACA-3′;
Human tau
Forward 5′-ACTTTGAACCAGGATGGCTGAGC-3′
Reverse 5′-CTGTGCATGGCTGTCCCTACCTT-3′;
Murine tau
Forward 5′-CCAGTTGTGTATGTCCACCC-3′
Reverse 5′-CTCAGCATCCCACCTGTAAC-3′
Disrupted murine tau
Forward 5′-AAGTTCATCTGCACCACCG-3′,
Reverse 5′-TGCTCAGGTAGTGGTTGTCG-3′ [20].
Nmnat1+/− and Nmnat1 tg were crossed with htau mice producing
the genotypes of interest that were all heterozygous for murine tau
(mtau+/−): htau, Nmnat1 tg/htau, Nmnat1+/−/htau. Control experi-
ments were ﬁrst carried out to verify the extent of tau pathology in
htau/mtau+/−mice. Behavioral data were further collected from re-
levant control mice (mtau+/−, Nmnat1 tg and Nmnat1+/− mice), in
comparison to wild type mice, as explained below and reported in the
supplementary information.
2.2. Study design
12 mice of each genotype (n = 6/sex) were subjected to a range of
tests relevant to AD measuring activities of daily living, learning and
memory. Locomotor activity and anxiety-related behavior were also
tested. Activities of daily living were measured using the food bur-
rowing test. Memory was assessed using spontaneous alternation in the
Y-maze, novel object location/discrimination test and contextual fear
conditioning. Open-ﬁeld was used to test locomotor and anxiety-related
behavior. A timeline of the experimental plan and behavioral experi-
ments is illustrated in Fig. 1A. The food burrowing test was repeated
from two to six months of age in a monthly interval, the spontaneous
alternation and open-ﬁeld tests were repeated at the age of 4 and 6
months and contextual fear conditioning was performed at the age of
six months only, as this test cannot be repeated. Behavioral assessment
was followed by in vivo magnetic resonance spectroscopy (MRS) and
magnetic resonance imaging (MRI) to assess metabolic and structural
changes in the hippocampus, after which tissue was collected for post-
mortem analyses.
2.3. Food-burrowing test
The protocol was adapted from Deacon et al. [26]. Mice were in-
dividually placed for one night in a novel cage with ad libitum access to
food and water. A glass jar containing 30 g of food pellet broken into
small pieces was added to the cage. The amount of food displaced from
the jar was measured. Data was transformed by square root in order to
conform them to a normal distribution [27] and analyzed using 3-way
ANOVA with sex and genotype and repeated measures over age, fol-
lowed by post-hoc planned comparisons.
2.4. Spontaneous alternation task
Spontaneous alternation was used to test spatial working memory as
previously described [28,29]. The Y-shaped maze comprised three
identical transparent Plexiglas® arms at a 120° angle from each other
(41.5 cm in length and 6 cm in width surrounded by 15 cm high
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transparent Perspex walls). The start point (6 cm x 7.5 cm) was located
in the center of the maze, and the animal was allowed to freely explore
the three arms over ﬁve minutes. The number of alternations was re-
corded and expressed as a percentage of alternation to estimate spatial
working memory performance [28,29]. Data was analyzed using 3-way
ANOVA with sex and genotype and repeated measures over age, fol-
lowed by post-hoc planned comparisons.
2.5. Open-ﬁeld
Open ﬁeld was used to assess locomotor and anxiety-related beha-
vior as previously described [29]. Mice were placed in Perspex activity
boxes (30 cm× 35 cm× 25 cm) for 30 min during which total dis-
tance moved (cm) and percentage of time spent in the center (s) were
recorded using Ethovision software (Noldus, Wagenigen, Netherlands).
Data was analyzed using 3-way ANOVA with sex and genotype and
repeated measures over age, followed by post-hoc planned compar-
isons.
2.6. Novel object location and recognition
Novel object location and novel object recognition were used to
measure spatial and recognition memory respectively, as previously
described [29]. Brieﬂy, this test consists of three separated trials: in the
habituation trial each mouse was allowed to explore two identical ob-
jects next to each other along one arena wall. After a 10-min-long in-
terval each mouse was placed into the same arena for the location trial,
with one of the two objects being moved across to the opposite wall.
After a 20-min inter-trial interval, each mouse was allowed to explore
the objects for a third time (discrimination trial) in which one object
had been exchanged. Total object exploration times, object location and
object discrimination times were recorded using Ethovision software
(Noldus, Wagenigen, Netherlands). Data was analyzed using 3-way
ANOVA with sex and genotype as between subject factors and repeated
measures over age, followed by post-hoc planned comparisons. For
each group, preference indices in the object tests were compared to
chance levels (50%) using one-sample t-tests, in order to determine if
the mice were able to discriminate the novel location or novel object.
2.7. Contextual fear conditioning (CFC)
Associative learning and memory were assessed using contextual
fear conditioning following a previously described protocol [29].
Brieﬂy, this test consisted of three trials conducted on three consecutive
days using the same chamber (25 cm× 25 cm× 38 cm): (1) in the
acquisition trial, mice were exposed to a series of ﬁve foot-shocks (1s-
long, 0.4 mA), each separated by a 60-s interval. (2) In the retention
trial, mice were placed in the same chamber for one minute without the
application of foot shocks. (3) In the one-minute-long extinction trial
foot shocks were also omitted. Analysis of the time that the mice spent
immobile was conducted in blind twice, and the data were averaged for
statistical analysis. Data from the acquisition trial were analyzed using
3-way ANOVA with sex and genotype as between subject factors and
repeated measures over time (minutes separating each shock applica-
tion), followed by post-hoc planned comparisons; data from retention
and extinction trials were analyzed using two-way ANOVA, followed by
post-hoc planned comparisons.
2.8. In vivo magnetic resonance spectroscopy and imaging
Animals were anaesthetized with 1% − 1.75% isoﬂurane in a ni-
trous oxide:oxygen = 2:1 gas mixture and placed in a custom built
holder inside the MR scanner to minimize head motion. Throughout the
study, breathing rate and body temperature were monitored con-
tinuously and kept constant through adjustment of anesthesia levels
and warm water circulation.
In vivo MRI and MRS data were acquired from mice of all four
genotypes (male and female, age = 6 months, Suppl. Table 1) using a
horizontal 7 T MR imaging system (Avance Biospec 70/30 USR; Bruker,
Karlsruhe, Germany) equipped with a volume transmit/surface receive
radiofrequency coil combination.
MR spectroscopy data were acquired from a 2 × 2× 2 mm3 voxel
(volume of interest) centered on the left hippocampus and positioned
with multi slice rapid acquisition with relaxation enhancement (RARE)
images [30] (Fig. 3A). A line-width of 10–15 Hz for the water peak was
obtained after adjustment of ﬁrst- and second-order shims with FAS-
TMAP [31]. A Point-Resolved Spin echo sequence (PRESS) [32] was
used to acquire the MR spectra (repetition time, TR = 2000 ms, echo
time, TE = 14 ms, 1024 signal averages) after water suppression with
variable pulse power and optimized relaxation delays (VAPOR) [33].
The total acquisition time was 34 min. All spectra processing was
conducted blinded to group assignment. Spectra were analyzed using
LCModel (Version 6.3-0I) [34]. Resonances corresponding to myo-in-
ositol (Ins), taurine, glutamate (Glu), N-acetylaspartate (NAA), gluta-
mine (Gln), glutathione (GSH), glycerophosphocholine and phosphati-
dylcholine (PCh + GPC), and creatine and phosphocreatine (Cr + PCr)
were quantiﬁed relative to the total metabolic content (Glu + PCh
+ GSH+ Ins + NAA+ Gln + Taurine + Cr + pCr). Only results
with the Cramer–Rao lower bounds ≤15% were included in the ana-
lysis. Data was further analyzed using ANOVA followed by Bonferroni
post-hoc test.
For anatomical MRI, 30 coronal slices were acquired using a RARE
sequence (256 × 256 matrix size, ﬁeld of view,
FOV = 1.66 × 1.66 cm, 0.3 mm slice thickness; TR = 7500 ms, eﬀec-
tive TE = 29.4 ms, RARE factor = 8, number of averages = 8). The
total acquisition time per volume was 32 min. What is referred to as
hippocampal areas (covered in 10+/− 1 coronal slices) in the context
of this work included ﬁelds CA1, CA2 and CA3, the pyramidal cell and
lacunosum moleculare layers, the stratum lucidum and radiatum of the
hippocampus as well as the dentate gyrus including its molecular,
polymorph and granular layers as well as the subiculum relating to
Figures. 39 –67 in The Mouse Brain Atlas by Paxinos & Franklin [35].
Hippocampal volumes were determined by manually drawing regions
of interest (Fig. 3D) in blind using a software [Medical Image Proces-
sing, Analysis and Visualization (MIPAV); v. 7.0.1; Center for In-
formation Technology (CIT), National Institutes of Health (NIH)]. The
mean of the hippocampal volume of the left and right hemispheres was
expressed as percentage of the total brain volume as outlined in The
Mouse Brain Atlas [35]. Since the hippocampal and whole-brain vo-
lume did not diﬀer across the two sexes they were combined within
each genotype for the statistical analysis of genotype diﬀerences. Data
was analyzed using ANOVA followed by Fisher’s LSD post-hoc test.
2.9. Tissue processing and staining
Mice were humanely killed using an approved Schedule 1 method
(cervical dislocation) at six-months-of-age, immediately after the MRS
procedure. Half brains from htau/mice, Nmnat1 tg/htau/mtau+/−,
Nmnat1+/−/htau/mtau+/− and mtau+/− mice were post-ﬁxed in 4%
PFA for a minimum of 48 h at room temperature. Brains were dehy-
drated by an ascending alcohol series and then embedded in paraﬃn.
Paraﬃn blocks were cut into coronal microtome sections (thickness
8 μm) and drawn up on microscope slides.
For evaluation of gross hippocampal morphology, 8 μm coronal
sections were mounted on Superfrost slides (BDH), air dried and stained
with Haematoxylin and Eosin (H&E). (n = 5/genotype). H&E stained
sections were imaged by low power (Plan-NEOFLUOAR 1.25X/0.035)
light microscopy (Zeiss Axioplan). Sections were matched between all
genotypes and used for the analysis and hippocampal areas were
measured using ImageJ software. Data were analyzed using one-way
ANOVA followed by Bonferroni post-hoc test.
For immunohistochemistry, cut sections were deparaﬃnized in
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xylene and rehydrated through decreasing concentrations of ethanol
before the immunohistochemical procedure. Sections were then rinsed
in water and subsequently incubated at room temperature in a solution,
containing 0.3% H2O2 diluted in PBS (0.1 mol/L, pH 7.4) for 30 min in
order to block endogenous peroxidases. After rinsing, sections were
treated with 10 mM sodium citrate buﬀer pH 6 for 20 min at 100 °C for
antigen retrieval. Sections were then incubated with mouse im-
munoglobulin G blocking reagent (mouse on mouse [MOM] Kit, Vector
Laboratories, Burlingame, CA) for 1 h in a humid chamber at room
temperature, subsequently incubated with monoclonal antibody CP13
(1:25, generously provided by Prof. Peter Davies, Bronx, NY, USA [21])
and developed with 3,3′-diaminobenzidine (DAB). Sections were
scanned and viewed using NanoZoomer digital slide scanner (Hama-
matsu, Japan).
2.10. Western immunoblotting
Freshly frozen hippocampi and cortices from all genotypes (n = 3-
5/genotype) were homogenized in RIPA lysis buﬀer containing pro-
tease and phosphatase inhibitors (Complete mini, Roche). The protein
samples were then loaded on a 10% SDS polyacrylamide gel and sub-
sequently transferred to nitrocellulose membrane using a semi-dry
blotting apparatus (BioRad). Membranes were blocked for 1 h in 5%
BSA in PBS plus 0.2% Tween-20 (PBST), incubated overnight with
primary antibody in 5% BSA at 4 °C and incubated for 1 h at RT with
HPRT-linked secondary antibody in 3% BSA in PBST. The following
primary antibodies were used: mouse anti-synaptophysin (Dako clone
Y38, 1:10000), Phospho-PHF-tau pSer202 + Thr205 (AT8, Pierce,
1:500). As loading controls, mouse anti-β-tubulinIII (Sigma, 1:5000)
and mouse anti-β-actin (Abcam, 1:5000) were used. Bands were vi-
sualized on ﬁlm using a chemiluminescent detection kit (GE
Healthcare). Data was analyzed using one-way ANOVA followed by
Bonferroni post-hoc test.
2.11. NMNAT enzyme activity assay and NAD level determination
Cortices and hippocampi of 6-month-old mice, collected at the end
of the MRS procedure, were snap-frozen in liquid nitrogen and stored at
−80 °C. On the day of use, tissues were homogenized in 0.5 M HEPES
buﬀer pH 7.5 and immediately processed for NAD level and NMNAT
enzyme activity determination. NAD was then quantiﬁed with the
HPLC-based assay as described previously [36] (n = 4/group). Data
was analyzed using one-way ANOVA followed by Bonferroni post-hoc
test.
2.12. Control experiments
2.12.1. Tau pathology in htau mice heterozygous for murine tau (htau/
mtau+/−)
These were compared to control wild type C57BL/6J mice (wild
type, Charles River UK). Previous characterization of htau mice has
been in the context of the homozygous deletion of murine tau as re-
moval of murine tau was found necessary for the tau pathology to occur
in htau mice [21]. However, we have found that murine tau knockout
mice develop a behavioral phenotype with aging which bears some
similarities to the behavioral phenotype of htau mice but progresses
more slowly [24] and, as reported previously, is associated with the
occurrence of systemic pathologies [37]. Since there is no evidence that
complete removal of murine tau is necessary for the tau pathology to
occur in htau mice, we ﬁrst tested whether a heterozygous murine tau
knockout background, which would prevent adverse eﬀects of murine
tau deletion, is suﬃcient for the pathology to occur by carrying out
western immunoblotting of total (Tau46), early (CP13) and late (PHF1)
pathological stage tau phosphorylation on cortical tissue from three-
four 6-month-old mice per genotype, as described previously [24].
These preliminary ﬁndings, reported in Suppl. Fig. 1, reveal similar
levels of total (Tau46, Suppl. Fig. 1. A&B) and phosphorylated (CP13:
Suppl. Fig. 1. C&D; PHF1: Suppl. Fig. 1. E&F) tau in htau mice, re-
gardless of whether they were bred on a full or heterozygous murine tau
knockout background. In htau mice, hyperphosphorylated tau was
found to redistribute from its axonal position to the cell body and
dendrites from 3 months of age [21]. In order to assess whether a si-
milar redistribution was also evident in htau mice heterozygous for
murine tau, immunohistochemistry was performed with CP13 antibody
[21]. We also found that tau is more abundant in the axons of wild type
mice (Suppl. Fig. 1G and I), while it redistributes to a perinuclear lo-
cation in htau mice which are heterozygous KO for murine tau (htau/
mtau+/− Suppl. Fig. 1H and J), similar to previous reports in htau mice
homozygous for the murine deletion [21]. These observations indicate
that reducing murine tau level by half is suﬃcient for the tau pathology
to develop in htau mice.
2.12.2. Behavioral characteristics of mtau+/−, nmnat1 tg and Nmnat1+/−
mice
We have previously reported that full murine tau knockout mice
(mtau−/−) display signiﬁcant hyperactivity from 4 months of age and
deﬁcits in food burrowing from 9 months of age, compared to wild type
C57BL/6J mice [24]. We therefore compared the performance of 4- and
6- months-old mtau+/− and wild type mice (n = 12/genotype) for
these two features and found no diﬀerences (Suppl. Table 2 and Suppl.
Fig. 2A and C). This indicates that potentially confounding eﬀects of
murine tau deletion in htau mice can be avoided with a heterozygous
murine tau knockout background without aﬀecting the occurrence of
tau pathology. Likewise, we assessed these behaviors sensitive to tau
dysfunction in Nmnat1 tg and Nmnat1+/− mice of the same ages
(n = 12/genotype) and found unaltered food burrowing performance
(Suppl. Fig. 2B) but Nmnat1 tg developed an hyperactive phenotype
with age (Suppl. Table 1 and Suppl. Fig. 2C).
3. Results
The eﬀect of sex/genotype/age interactions and results of the
ANOVA for behavioral variables are reported in Table 1.
3.1. NMNAT1 overexpression rescues an early impairment in food
burrowing performance in htau mice
Subtle behavioral abnormalities, preceding cognitive dysfunction,
are among early signs in AD [38]. In htau mice, cognitive decline has
been detected by 12 months of age [39], but we have found earlier non-
cognitive behavioral abnormalities in the food burrowing test emerging
by 4 months of age, after onset of tau pathology [24]. This test has been
used to assess activities of daily living and the inability to perform these
activities is an early sign of AD [27]. We therefore subjected the mice to
the food burrowing test from 2 months to 6 months of age. There were
signiﬁcant genotype (F(3.64) = 4.63; p = 0.005) and age X genotype
interaction (F(12,237) = 1.82; p = 0.046) eﬀects, regardless of sex, but
females overall performed better in this task (F(1.64) = 13.96;
p < 0.001). htau/mtau+/−mice showed a marked impairment in food
burrowing (p < 0.05 compared to wild type at 2, 3, 4 and 6 months of
age, Fig. 1B–F). Strikingly, we found that increasing NMNAT1 levels
improved the food burrowing performance from 3 months of age and at
all later points (Fig. 1C–F), but not at 2 months of age. However, re-
ducing NMNAT1 levels did not further decrease the htau/mtau+/−
mice’s impaired performance (Fig. 1B–F). Thus, NMNAT1 deﬁciency
does not contribute to food burrowing impairment in htau/mtau+/−
mice, but NMNAT1 overexpression rescues this deﬁcit.
3.2. Locomotor activity is increased in htau/mtau+/− mice overexpressing
NMNAT1
We assessed locomotor activity and anxiety-related behavior in mice
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of all genotypes using the open ﬁeld. Anxiety-related behavior did not
diﬀer between the genotypes at both four and six months of age
(Table 1 and Fig. 2A and D). Interestingly, there were signiﬁcant gen-
otype (F(3.64) = 5.72; p = 0.002) and age X genotype interaction
(F(3.64) = 2.94; p = 0.04) eﬀects for locomotor activity (Table 1) which
was higher in six month old htau/mtau+/− mice overexpressing
NMNAT1 than in the other genotypes (Fig. 2A). This age-dependent
higher activity is linked to NMNAT1 overexpression as it was also ob-
served in Nmnat1 tg mice compared to wild type mice (Suppl. Fig. 2D
and Suppl. Table 2).
3.3. htau/mtau+/− mice do not show learning and memory deﬁcits at six-
months-of-age
In the spontaneous alternation test, mice of all genotypes alternated
arms with a frequency higher than chance without statistically sig-
niﬁcant diﬀerences across the genotypes (Table 1, Fig. 2C and F).
Likewise, mice of all genotypes displayed a comparable performance in
object recognition and location both at 4 (Suppl. Fig. 3A, C and E) and 6
(Suppl. Fig. 3B, D and F) months, as tested by the novel object para-
digm. In the contextual fear conditioning test, during the acquisition
trial, all mice were able to acquire contextual fear (F(4;120) = 135.69;
p < 0.001. Table 1 and Fig. 2G). No signiﬁcant diﬀerences were de-
tected between the diﬀerent genotypes in contextual memory retention
and extinction (Table 1 and Fig. 2G–H).
3.4. Absence of neurodegenerative changes in the htau mouse brain
We then asked whether any sign of neurodegeneration in the htau/
mtau+/− mouse brains could explain the speciﬁc defect seen in the
food burrowing test (Fig. 1), which has been found to be linked to
hippocampal and cortical integrity [40,41]. First, we measured non-
invasively the levels of Ins, taurine, Glu, NAA, Gln, GSH, PCh + GPC,
and total creatine (Cr + PCr) in vivo using MRS in the hippocampus of
six-month-old mice, as the level of these metabolites was found to
change during neurodegenerative processes [42,43]. We did not ob-
serve any statistically signiﬁcant diﬀerence in metabolite levels, as-
sessed by MRS across the four genotypes at the time point studied
(Fig. 3C). We also measured the volume of the hippocampus in vivo
(Fig. 3E) and post-mortem (Fig. 4A and B) and found no diﬀerences
across the genotypes. Finally, we determined the levels of the synaptic
marker synaptophysin in the hippocampus (Fig. 4E) and cortex (Fig. 5F)
and no signiﬁcant changes were detected in all genotypes.
Taken together, these data show that downregulation of NMNAT1
levels does not cause metabolic or neurodegenerative changes in the
brain of htau/mtau+/− mice up to six months of age and that rescue of
the early behavioral abnormality, i.e. the reduced performance in the
food burrowing test, by NMNAT1 overexpression may not be due to its
neuroprotective property.
3.5. NAD levels are not aﬀected by changes in NMNAT enzyme activity
We determined NMNAT enzyme activity and NAD levels in the
cortex and hippocampus of htau/mtau+/− mice. Overexpression or
downregulation of NMNAT1 in htau/mtau+/− mice had expected
corresponding eﬀect on enzymatic activity, which was reduced in
Nmnat1+/−/htau/mtau+/− mice and increased in Nmnat1tg/htau/
mtau+/− mice (Fig. 5A-B). Changes in enzymatic activity were not
associated with alterations in steady-state NAD levels (Fig. 5C–D). This
indicates that behavioral eﬀects of NMNAT1 overexpression in htau/
mtau+/− are not caused by detectable changes in NAD levels.
3.6. Levels of hyperphosphorylated tau in brains of htau mice are reduced
by NMNAT1 overexpression
We showed previously that deﬁcits in food burrowing develop after
onset of tau hyperphosphorylation in htau mice [24]. Therefore in
order to test whether behavioral eﬀects of NMNAT1 overexpression are
associated with changes in hyperphosphorylated tau, western im-
munoblotting of AT8 were performed in the cortex (Fig. 5E) and
Table 1
Results of the ANOVA tests on behavioral measures in htau/mtau+/− mice.
Num. df Den. df F-value p-value
Food burrowing test
sex 1 64 13.96 <0.001
genotype 3 64 4.63 0.005
age 4 237 13.65 <0.001
sex X genotype 3 64 0.37 0.778
sex X age 4 237 0.93 0.449
genotype X age 12 237 1.82 0.046
sex X genotype X age 12 237 0.71 0.741
Acquisition of contextual fear
sex 1 30 0.11 0.737
genotype 3 30 0.04 0.988
minute 4 120 135.69 < 0.001
sex X genotype 3 30 0.04 0.987
sex X minute 4 120 1.82 0.13
genotype X minute 12 120 0.4 0.962
sex X genotype X minute 12 120 0.74 0.71
Retention of contextual fear
sex 1 8.19 0.08 0.775
genotype 3 74.47 0.76 0.527
sex X genotype 3 51.48 0.52 0.67
Extinction of contextual fear
sex 1 2.05 0.08 0.775
genotype 3 18.62 0.76 0.527
sex X genotype 3 12.87 0.52 0.67
Novel object habituation
sex 1 64 0.54 0.466
genotype 3 64 0.62 0.603
age 1 64 2.1 0.152
sex X age X genotype 3 64 0.07 0.976
sex X age 1 64 1 0.321
genotype X age 3 64 1.03 0.386
sex X genotype X age 3 64 0.25 0.858
Novel object location
sex 1 64 0.09 0.771
genotype 3 64 0.3 0.827
age 1 64 7.17 0.009
sex X genotype 3 64 0.58 0.633
sex X age 1 64 5.81 0.019
genotype X age 3 64 1.11 0.35
sex X genotype X age 3 64 1.06 0.372
Novel object discrimination
sex 1 64 0.31 0.58
genotype 3 64 1.19 0.319
age 1 64 0.37 0.548
sex X genotype 3 64 1.73 0.17
sex X age 1 64 1.8 0.184
genotype X age 3 64 0.77 0.516
sex X genotype X age 3 64 1.1 0.358
Open ﬁeld (locomotor activity)
sex 1 64 2.75 0.102
genotype 3 64 5.72 0.002
age 1 64 53.11 < 0.001
sex X genotype 3 64 2.28 0.088
sex X age 1 64 0.86 0.358
genotype X age 3 64 2.94 0.04
sex X genotype X age 3 64 0.7 0.558
Open ﬁeld (anxiety index)
sex 1 64 1.42 0.238
genotype 3 64 0.96 0.417
age 1 64 0 0.966
sex X genotype 3 64 0.52 0.668
sex X age 1 64 1.72 0.194
genotype X age 3 64 2.75 0.05
sex X genotype X age 3 64 1.95 0.131
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hippocampus (Fig. 5F), as both regions were found to mediate food
burrowing performance [40,41]. AT8 levels were signiﬁcantly in-
creased in the cortex of htau/mtau+/− mice and this was prevented by
overexpressing NMNAT1 in Nmnat1tg/htau/mtau+/− mice (Fig. 5 E).
In contrast, in the hippocampus, AT8 levels in htau/mtau+/− mice
were signiﬁcantly increased only when NMNAT1 was downregulated
(Fig. 5F). These results ﬁrst suggest that tau pathology develop faster in
the cortex than hippocampus, as seen in other models of tauopathy
(mtau and rTg4510 lines) [44,45]. They also suggest that over-
expressing NMNAT1 in htau/mtau+/− mice may protect against tau
hyperphosphorylation, possibly contributing to alleviation of early be-
havioral deﬁcits.
4. Discussion
NMNAT1 plays an important role in neuron maintenance and its
Fig. 1. Food burrowing performance in htau/mtau+/− mice is improved by NMNAT1 overexpression. The timeline of in vivo assessment is detailed in panel (A). Food-burrowing
performance was assessed at two (B), three (C), four (D), ﬁve (E) and six (F) months of age. At the age of two months (B), burrowing behavior was strongly impaired in all genotypes
compared to wild type control mice. However, from three- to six-months-of-age (C-F), increasing NMNAT1 levels in htau/mtau+/− mice progressively rescued their food burrowing
deﬁcit, whilst reducing NMNAT1 levels did not further decrease their low performance. (n = 12/group, three-way ANOVA *, p < 0.05 compared to wild type mice.).
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loss of function causes neurodegeneration [11]. In addition, NMNAT1 is
neuroprotective in several animal models of neurodegenerative dis-
orders [19]. Our study extends these observations to a mouse model of
tauopathy relevant to AD as we found that overexpressing NMNAT1 in
mice which express wild type human tau rescues an early behavioral
deﬁcit associated with the development of tau pathology [24].
However, cerebral morphometry and cognitive deﬁcits, which are not
yet present at this stage of the pathology, were not induced by
NMNAT1downregulation. The lack of diﬀerences in cognitive deﬁcits is
in contrast with previous ﬁndings that reported an impairment in vi-
suospatial learning and memory in Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
mouse (htau mice), at six months of age [46]. However, in this pilot
Fig. 2. Locomotor activity of 6-months-old Nmnat1 tg/htau mice is increased. Locomotor activity and anxiety-related behavior were assessed using the open ﬁeld test while spatial
working memory was assessed in the spontaneous alternation test at 4 and 6 months of age. Contextual fear conditioning behavior was evaluated at 6 months of age. As an index of
anxiety-like behavior, the proportion of time the mice spent in the center was measured, but no diﬀerence was detected between the genotypes at four- (A) and six-months-of-age (D).
Locomotor activity, represented as the total distance moved (cm) over 30 min, did not diﬀer between all genotypes at four–months-of-age (B), but was higher in htau/mtau+/− mice
overexpressing NMNAT1 at six months-of-age (E). Regardless of age, spatial working memory (C and F), acquisition, retention and extinction of contextual fear (G, H and I) did not diﬀer
between genotypes. (n = 12/group, three-way ANOVA; *, p < 0.05 compared to wild type mice).
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study, only three mice were used and tested with diﬀerent behavioral
tests, based on operant conditioning while, in contrast, our tasks aimed
to explore spontaneous exploration.
The htau mouse provides a model to study tau pathology relevant to
AD through the expression of non-mutant human tau that develops a
neuropathology which is reminiscent of that occurring in the early
stages of AD [21,24,39]. The food burrowing test exploits a natural
rodent behavior which requires the integrity of the hippocampus and
frontal cortex (brain areas particularly sensitive to AD-like pathology)
and is aﬀected following lesions of these brain areas [26,41]. The ﬁrst
evident symptom in AD is a deterioration in the ability to perform
‘daily-life activity’ which, in mouse models, correspond to burrowing
and nest construction [27]. Although behavioral screening in AD
patients are mainly focused on cognitive tests, it may be important to
assess more speciﬁc behaviors which, as suggested by our results, could
be modiﬁed at early stage. We found that increasing NMNAT1 levels in
htau/mtau+/− mice progressively rescued the speciﬁc food burrowing
deﬁcit at three, four and six months of age, which may be related to a
protective eﬀect of NMNAT1 on tau hyperphosphorylation in the
cortex. This protective eﬀect might develop with age, which could ex-
plain the lack of protection at the ﬁrst time point tested. Reducing
NMNAT1 levels did not further decrease the food burrowing perfor-
mance of htau mice; this may be due to the fact that the deﬁcit of the
htau mouse was already pronounced producing a ceiling eﬀect, or to
the fact that NMNAT1 overexpression has a greater impact on NMNAT
activity (+200%) than its downregulation (-75%), since baseline
Fig. 3. Hippocampal metabolite levels and volume of htau/mtau+/− mice are not altered by modulation of NMNAT1 levels. Relative metabolite concentrations were assessed in vivo
using MRS with the voxel of interest being positioned in the left hippocampus (2 × 2× 2 mm3) as shown (A). Representative MRS spectrum. Selected metabolites: myo-inositol (Ins),
taurine (Tau), glutamate (Glu), N-acetylaspartate (NAA), glutamine (Gln), glutathione (GSH), glycerophosphocholine and phosphatidylcholine (PCh + GPC), and creatine and phos-
phocreatine (Cr + PCr) (B). Selected metabolite levels were quantiﬁed with respect to the total metabolite content as detailed in methods and were unaltered by the genotypes (C). For 3D
anatomical MRI, coronal slices were acquired using a RARE sequence and hippocampal volumes were determined in blind by manually drawing regions of interest around the left and
right hippocampus, as shown in (D). No diﬀerences were detected across the genotypes (E).
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NMNAT activity is moderate. However, the fact that NMNAT1 down-
regulation appear to have opposite eﬀects on tau phosphorylation in the
cortex and the hippocampus could also contribute to the lack of ex-
acerbation of burrowing behavior which is mediated by both brain
regions [40,41].
Interestingly, we found that htau/mtau+/− mice overexpressing
NMNAT1 retain the signiﬁcant increase in locomotor activity also
evident in six-months-old Nmnat1 tg mice compared to their wild-type
littermates. Overexpression of NMNAT1 has been proposed to delay
aging and improve metabolism ([47] and Rossi, Conforti et al., un-
published), an observation that could explain why Nmnat1 tg mice are
more active.
To gain understanding of the mechanisms underlying the modula-
tion of features characteristic of tauopathy in htau mice by alteration in
Fig. 4. Absence of neurodegenerative changes in the cortex and hippocampus of htau/mtau+/− mice. (A) Coronal sections of brains from all genotypes stained with H-E and (B) relative
quantiﬁcation of the hippocampal areas are shown. Scale bar, 500 μm. There were no diﬀerences in the hippocampal area across all genotypes (n = 5/group, one-way ANOVA with
Bonferroni post-hoc test, compared to the wild type). (E-F) Western blots of homogenates from hippocampus (C) and cortex (D) were probed with an antibody against the presynaptic
marker synaptophysin and with β-tubulin as a loading control. Quantiﬁcation of the density relative to the loading control showed no diﬀerence in the hippocampus (C) and in the cortex
(D) (n = 5/group. one-way ANOVA with Bonferroni post-hoc test, compared to control wild type mice).
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Fig. 5. Changes in NMNAT enzyme activity and hyperphosphorylated tau levels. NMNAT enzyme activity (A, B) and NAD levels (C, D) were measured in extracts of cortex (A, C) and
hippocampus (B, D). NMNAT1 level modulation changes the enzyme activity but not the NAD levels. Enzyme activity is signiﬁcantly reduced in Nmnat1+/−/htau/mtau+/− and
increased in Nmnat1 tg/htau/mtau+/− mice in both the hippocampus and cortex. However, NAD levels did not change by increasing or reducing NMNAT1 in the cortex (C) and
hippocampus (D). Levels of hyperphosphorylated tau in cortex of htau/mtau+/− mice appear reduced by Nmnat1 overexpression. Western blots of cortex (E) and hippocampus (F)
homogenates probed with antibody AT8 and their relative quantiﬁcation indicate that tau immunoreactivity, evident in the cortex of htau/mtau+/− and in the hippocampus of Nmnat1+/
−/htau/mtau+/− mice, are decreased in Nmnat1 tg/htau/mtau+/− mice (n = 4/group). One-way ANOVA with Bonferroni post-hoc test, compared to wild type mice. *, p < 0.05.
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NMNAT1 levels, we compared brain metabolite levels between geno-
types in vivo, using MRS. This method has been widely used to study
cellular mechanisms preceding complex pathological conditions [48]
such as in models of amyloidosis and Pick disease [49,50]. Changes in
speciﬁc metabolites may indicate the onset or the course of speciﬁc
neurodegenerative processes, therefore measuring brain metabolism
might be a sensitive method to screen for early biomarkers of pa-
thology. For example, NAA, a neuronal marker, is reduced in the medial
temporal lobe in AD patients that show only mild cognitive impair-
ments [51]. Taurine, which plays a role in osmoregulation and neuro-
protection in the central nervous system, is also reduced in a murine
mouse model of amyloidosis [52]. Several lines of evidence suggest that
other metabolites, such as myo-inositol, a glial marker, Glu, Gly, and
choline, are changed in AD [53,54]. In the present study, the metabolic
contents of the hippocampus in six month old htau/mtau+/− mice re-
mained unchanged. Likewise, no gross structural changes were detected
in the presence of human tau as determined by in vivo MRI and post-
mortem tissue. However, these sensitive methods were able to detect
changes in other more aggressive models of tauopathies [55] and the
lack of changes is therefore consistent with the lack of aggravation of
tau pathology by downregulation of NMNAT1.
NMNAT enzyme activity in htau/mtau+/− mice was similar to that
of their control littermate mtau+/, while it was increased when
NMNAT1 was overexpressed and decreased when NMNAT1 was
downregulated, in agreement to corresponding changes in activity in
Nmnat1 tg and Nmnat1+/− mice [22,23]. Despite the modulation of
NMNAT enzyme activity, which correlated to its levels of expression,
steady-state NAD levels were not signiﬁcantly diﬀerent in all genotypes.
Genetic overexpression of NMNAT in muscle was also found to have
modest eﬀects on NAD concentrations, which were thought to be
maintained at a steady-state levels through a negative feedback me-
chanism [56]. We, however, cannot rule out that the increased NMNAT
activity could cause localized changes in NAD availability and therefore
aﬀect the activity of downstream NAD dependent enzymes. In support
of this, recent observations correlate nuclear NAD changes sensitive to
the levels of NMNAT1 with sirtuin 1 (SIRT1), a NAD-dependent dea-
cethylase, and disruption of nuclear-mitochondrial communication
[47]. A number of mitochondrial proteins, involved in oxidative
phosphorylation and other metabolic pathways were found altered in
the cerebral cortices of 6 month old males 3xTg-AD which develop tau
pathology as well as amyloid deposition [57]. Importantly, these al-
terations were found to precede amyloid deposition and neuroﬁbrillary
tangles formation, suggesting mitochondrial dysregulation as an early
event in the pathogenesis of Alzheimer’s disease [58]. Although muscle
data failed to observe alterations in mitochondrial NAD content fol-
lowing genetic overexpression of NMNAT [56], possible changes in
mitochondrial homeostasis amongst the diﬀerent NMNAT1 genotypes
would support the hypothesis of localized variations of NAD availability
and could be associated with more subtle neurodegenenerative
changes. This will need to be investigated in further studies.
4.1. The protective eﬀects of NMNAT1 overexpression in htau mice could be
mediated by SIRT1, regardless of changes in NAD concentrations
SIRT1 is ubiquitously present in areas of the brain especially sus-
ceptible to age-related neurodegenerative states (e.g., the prefrontal
cortex, hippocampus and basal ganglia) [59] and was found able to
reduce the level of tau aggregates by promoting deacetylation and
clearance of toxic tau species, a mechanism thought to be dependent
upon nuclear NAD availability [60]. But SIRT1 activation could also be
mediated by an increase in the cellular ratio of NAD to its reduced form
NADH [56,61] which is known to occur in response to an increased in
NMAPT expression and activity [62] and can be associated with
changes in enzymatic activity independently from changes in NAD
concentrations [61,62].
SIRT1 may also be involved in the delayed protection by NMNAT1
overexpression of the food burrowing deﬁcit characteristic of htau
mice. While NMNAT1 is located into the nucleus [7], SIRT1 shows
dynamic changes in its subcellular localization during development and
as a function of stress status [63]. In the mouse heart, SIRT1 is ex-
clusively expressed in the nucleus at embryonic stages, but found in
both the nucleus and cytoplasm at adulthood [64]. Although SIRT1
subcellular localization remains predominantly nuclear in the adult
healthy brain [59], where it facilitates tau clearance [60], this redis-
tribution could contribute to onset of tau pathology and associated
early deﬁcits in food burrowing behavior. Cellular stress, as is induced
by tau accumulation [65], was found to trigger nuclear transport of
SIRT1 [63], as well as alternative splicing of neuronal NMNAT towards
the cytoplasmic variant which has robust neuroprotective capacity
[66]. As such, the onset of tau pathology could switch NMNAT1 to-
wards enhanced neuroprotective functions, in part via dynamic changes
in SIRT1 subcellular localization. This mode of action could also pos-
sibly explain the diﬀerential eﬀects of NMNAT1 downregulation on
phosphorylated tau levels in the hippocampus and cerebral cortex, in
which tau pathology develops at a diﬀerent rate as. Insuﬃcient nuclear
SIRT1 levels is a possible mechanism whereby reducing NMNAT1 level
by half could accelerate the onset of tau hyperphosphorylation. Our
hippocampus data are indeed in agreement with previous observation
in a Drosophila model of tauopathy in which it was found that down-
regulation of NMNAT accelerates the development of tau pathology
[18]. It is however unclear why downregulation of NMNAT1 attenuated
tau phosphorylation in the cortex, where the pathology developed
earlier. Although one limitation of our study is that we only assessed
tau hyperphosphorylation using AT8 immunoblotting, it is possible that
reducing NMNAT1 level by half is not suﬃcient to prevent a neuro-
protective response to tau accumulation when the pathology pro-
gresses. Altogether, this suggests that neuroprotective eﬀects of
NMNAT1 on behavioral symptoms, and possibly tau pathology, would
only occur after disease onset, as was also seen in a Drosophila model of
tauopathy [18]. The implication of SIRT1 in the age-dependency of the
beneﬁcial eﬀects of nmnat1will need to be addressed in future studies.
In addition, protective eﬀects of NMNAT could also be linked to its
chaperone-like activity as seen in models a of polyQ toxicity [64] and in
a Drosophila model of tauopathy where the chaperone function of
NMNAT was found to contribute to tau clearance [18]. A similar ex-
planation was proposed for the neuroprotective eﬀect of lentiviral ex-
pression of NMNAT1 or NMNAT2 in the hippocampus of a mouse model
of tauopathy [19].
5. Conclusion
In summary, we show that the reported early, speciﬁc behavioral
deﬁcit in food burrowing observed in htau mice [24] can be alleviated
when NMNAT1 is overexpressed. The capability of NMNAT1 to notably
ameliorate the food burrowing performance in the htau mouse model at
very early stage highlights the potential for NMNAT1 to be a target for
early stage AD and other pathologies, but the underlying mechanisms
need to be addressed in future studies.
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